Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Psoriasis - Pipeline Review, H1 2018, provides an overview of the Psoriasis (Immunology) pipeline landscape.
Psoriasis is a chronic skin condition caused by an overactive immune system. Symptoms of the disease include shedding of cells, flared up skin, itchiness, and burning sensation, swollen and stiff joints. Predisposing factors include heredity, side effects of certain medicines, stress, infections and environmental conditions. The condition may be controlled by topical or systemic medications and phototherapy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Psoriasis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Psoriasis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Psoriasis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Psoriasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 18, 21, 46, 45, 2, 107, 33 and 10 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 5 molecules, respectively.
Psoriasis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Psoriasis (Immunology).
- The pipeline guide reviews pipeline therapeutics for Psoriasis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Psoriasis (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Psoriasis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Psoriasis (Immunology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Psoriasis (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Psoriasis (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
Table of Contents 2
Introduction 8
Psoriasis - Overview 9
Psoriasis - Therapeutics Development 10
Psoriasis - Therapeutics Assessment 41
Psoriasis - Companies Involved in Therapeutics Development 57
Psoriasis - Drug Profiles 120
Psoriasis - Dormant Projects 644
Psoriasis - Discontinued Products 662
Psoriasis - Product Development Milestones 666
Appendix 680
List of Tables
Number of Products under Development for Psoriasis, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Psoriasis - Pipeline by 3SBio Inc, H1 2018
Psoriasis - Pipeline by AbbVie Inc, H1 2018
Psoriasis - Pipeline by Abeome Corp, H1 2018
Psoriasis - Pipeline by AbGenomics International Inc, H1 2018
Psoriasis - Pipeline by Aclaris Therapeutics Inc, H1 2018
Psoriasis - Pipeline by Adello Biologics LLC, H1 2018
Psoriasis - Pipeline by Affibody AB, H1 2018
Psoriasis - Pipeline by Alfacyte Ltd, H1 2018
Psoriasis - Pipeline by Allergan Plc, H1 2018
Psoriasis - Pipeline by Almirall SA, H1 2018
Psoriasis - Pipeline by Alteogen Inc, H1 2018
Psoriasis - Pipeline by Amgen Inc, H1 2018
Psoriasis - Pipeline by AnaptysBio Inc, H1 2018
Psoriasis - Pipeline by ApoPharma Inc, H1 2018
Psoriasis - Pipeline by Arbor Pharmaceuticals LLC, H1 2018
Psoriasis - Pipeline by Arrien Pharmaceuticals LLC, H1 2018
Psoriasis - Pipeline by AstraZeneca Plc, H1 2018
Psoriasis - Pipeline by Athenex Inc, H1 2018
Psoriasis - Pipeline by Atlantic Bio Sci LLC, H1 2018
Psoriasis - Pipeline by Aurigene Discovery Technologies Ltd, H1 2018
Psoriasis - Pipeline by Baliopharm AG, H1 2018
Psoriasis - Pipeline by Bayer AG, H1 2018
Psoriasis - Pipeline by Beta Pharma Inc, H1 2018
Psoriasis - Pipeline by BioApex sro, H1 2018
Psoriasis - Pipeline by Biocad, H1 2018
Psoriasis - Pipeline by Biocon Ltd, H1 2018
Psoriasis - Pipeline by BioLingus AG, H1 2018
Psoriasis - Pipeline by Bionomics Ltd, H1 2018
Psoriasis - Pipeline by Bionovis SA, H1 2018
Psoriasis - Pipeline by BirchBioMed Inc, H1 2018
Psoriasis - Pipeline by Boehringer Ingelheim GmbH, H1 2018
Psoriasis - Pipeline by Boston Pharmaceuticals Inc, H1 2018
Psoriasis - Pipeline by Brickell Biotech Inc, H1 2018
Psoriasis - Pipeline by Bristol-Myers Squibb Co, H1 2018
Psoriasis - Pipeline by C4X Discovery Holdings PLC, H1 2018
Psoriasis - Pipeline by CalciMedica Inc, H1 2018
Psoriasis - Pipeline by Can-Fite BioPharma Ltd, H1 2018
Psoriasis - Pipeline by Celgene Corp, H1 2018
Psoriasis - Pipeline by Celon Pharma SA, H1 2018
Psoriasis - Pipeline by ChemoCentryx Inc, H1 2018
Psoriasis - Pipeline by ChironWells GmbH, H1 2018
Psoriasis - Pipeline by Coherus BioSciences Inc, H1 2018
Psoriasis - Pipeline by Compugen Ltd, H1 2018
Psoriasis - Pipeline by Concenter BioPharma Silkim Ltd, H1 2018
Psoriasis - Pipeline by conoGenetix biosciences GmbH, H1 2018
Psoriasis - Pipeline by Crescita Therapeutics Inc, H1 2018
Psoriasis - Pipeline by Dermala Inc, H1 2018
Psoriasis - Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittel, H1 2018
Psoriasis - Pipeline by DURECT Corp, H1 2018
Psoriasis - Pipeline by Eli Lilly and Co, H1 2018
Psoriasis - Pipeline by ELORAC Inc, H1 2018
Psoriasis - Pipeline by Exicure Inc, H1 2018
Psoriasis - Pipeline by Forward Pharma AS, H1 2018
Psoriasis - Pipeline by Fresenius SE & Co KGaA, H1 2018
Psoriasis - Pipeline by FYB202 GmbH & Co KG, H1 2018
Psoriasis - Pipeline by Galapagos NV, H1 2018
Psoriasis - Pipeline by Galderma SA, H1 2018
Psoriasis - Pipeline by Galectin Therapeutics Inc, H1 2018
Psoriasis - Pipeline by Genentech Inc, H1 2018
Psoriasis - Pipeline by Genfit SA, H1 2018
Psoriasis - Pipeline by Genor BioPharma Co Ltd, H1 2018
Psoriasis - Pipeline by GlaxoSmithKline Plc, H1 2018
Psoriasis - Pipeline by GlycoMar Ltd, H1 2018
Psoriasis - Pipeline by Grunenthal GmbH, H1 2018
Psoriasis - Pipeline by HitGen LTD, H1 2018
List of Figures
Number of Products under Development for Psoriasis, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Top 10 Routes of Administration, H1 2018
Number of Products by Stage and Top 10 Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018
